Cryptic deletions in balanced de novo translocations represent a frequent cause of abnormal phenotypes, including Mendelian diseases. In this study, we describe a patient with multiple congenital abnormalities, such as late-onset congenital adrenal hyperplasia (CAH), primary ovarian failure and Ehlers-Danlos syndrome (EDS), who carries a de novo t(6;14)(p21;q32) translocation. Genomic array analysis identified a cryptic 1.1-Mb heterozygous deletion, adjacent to the breakpoint on chromosome 6, extending from 6p21.33 to 6p21.32 and affecting 85 genes, including CYP21A2,TNXB and MSH5. Multiplex ligation-dependent probe amplification analysis of the 6p21.3 region was performed in the patient and her family and revealed a 30-kb deletion in the patient's normal chromosome 6, inherited from her mother, resulting in homozygous loss of genes CYP21A1P and C4B. CYP21A2 sequencing showed that its promoter region was not affected by the 30-kb deletion, suggesting that the deletion of other regulatory sequences in the normal chromosome 6 caused a loss of function of the CYP21A2 gene. EDS and primary ovarian failure phenotypes could be explained by the loss of genes TNXB and MSH5, a finding that may contribute to the characterization of disease-causing genes. The detection of this de novo microdeletion drastically reduced the estimated recurrence risk for CAH in the family.

1.
Araujo RS, Mendonca BB, Barbosa AS, Lin CJ, Marcondes JA, et al: Microconversion between CYP21A2 and CYP21A1P promoter regions causes the nonclassical form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 92:4028-4034 (2007).
2.
Baptista J, Mercer C, Prigmore E, Gribble SM, Carter NP, et al: Breakpoint mapping and array CGH in translocations: comparison of a phenotypically normal and an abnormal cohort. Am J Hum Genet 82:927-936 (2008).
3.
Bedeschi MF, Colombo L, Mari F, Hofmann K, Rauch A, et al: Unmasking of a recessive SCARF2 mutation by a 22q11.12 de novo deletion in a patient with Van den Ende-Gupta syndrome. Mol Syndromol 1:239-245 (2010).
4.
Billerbeck AE, Mendonca BB, Pinto EM, Madureira G, Arnhold IJ, Bachega TA: Three novel mutations in CYP21 gene in Brazilian patients with the classical form of 21-hydroxylase deficiency due to a founder effect. J Clin Endocrinol Metab 87:4314-4317 (2002).
5.
Borg I, Squire M, Menzel C, Stout K, Morgan D, et al: A cryptic deletion of 2q35 including part of the PAX3 gene detected by breakpoint mapping in a child with autism and a de novo 2;8 translocation. J Med Genet 39:391-399 (2002).
6.
Burch GH, Gong Y, Liu W, Dettman RW, Curry CJ, et al: Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 17:104-108 (1997).
7.
Chen W, Kim MS, Shanbhag S, Arai A, VanRyzin C, et al: The phenotypic spectrum of contiguous deletion of CYP21A2 and tenascin XB: quadricuspid aortic valve and other midline defects. Am J Med Genet A 149A:2803-2808 (2009).
8.
Costa-Barbosa FA, Tonetto-Fernandes VF, Carvalho VM, Nakamura OH, Moura V, et al: Superior discriminating value of ACTH-stimulated serum 21-deoxycortisol in identifying heterozygote carriers for 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 73:700-706 (2010).
9.
Cox JJ, Holden ST, Dee S, Burbridge JI, Raymond FL: Identification of a 650 kb duplication at the X chromosome breakpoint in a patient with 46,x,t(x;8)(q28;q12) and non-syndromic mental retardation. J Med Genet 40:169-174 (2003).
10.
Cozzolino M, Augello B, Carella M, Palumbo O, Tavazzi B, et al: Chromosomal 17p13.3 microdeletion unmasking recessive Canavan disease mutation. Mol Genet Metab 104:706-707 (2011).
11.
De Gregori M, Ciccone R, Magini P, Pramparo T, Gimelli S, et al: Cryptic deletions are a common finding in ‘balanced' reciprocal and complex chromosome rearrangements: a study of 59 patients. J Med Genet 44:750-762 (2007).
12.
Edelmann W, Cohen PE, Kneitz B, Winand N, Lia M, et al: Mammalian MutS homologue 5 is required for chromosome pairing in meiosis. Nat Genet 21:123-127 (1999).
13.
Fonseca AC, Bonaldi A, Costa SS, Freitas MR, Kok F, Vianna-Morgante AM: PLP1 duplication at the breakpoint regions of an apparently balanced t(x;22) translocation causes Pelizaeus-Merzbacher disease in a girl. Clin Genet 83:169-174 (2013).
14.
Gribble SM, Prigmore E, Burford DC, Porter KM, Ng BL, et al: The complex nature of constitutional de novo apparently balanced translocations in patients presenting with abnormal phenotypes. J Med Genet 42:8-16 (2005).
15.
Her C, Doggett NA: Cloning, structural characterization, and chromosomal localization of the human orthologue of Saccharomyces cerevisiae MSH5 gene. Genomics 52:50-61 (1998).
16.
Kulikowski LD, Bellucco FT, Nogueira SI, Christofolini DM, Smith Mde A, et al: Pure duplication 1q41-qter: further delineation of trisomy 1q syndromes. Am J Med Genet A 146A:2663-2667 (2008).
17.
L'Allemand D, Tardy V, Gruters A, Schnabel D, Krude H, Morel Y: How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 85:4562-4567 (2000).
18.
Lee HH, Chang JG, Tsai CH, Tsai FJ, Chao HT, Chung B: Analysis of the chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency. Clin Chem 46:606-611 (2000).
19.
Lindstrand A, Schoumans J, Gustavsson P, Hanemaaijer N, Malmgren H, Blennow E: Improved structural characterization of chromosomal breakpoints using high resolution custom array-CGH. Clin Genet 77:552-562 (2010).
20.
Lupski JR, Stankiewicz P: Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet 1:e49 (2005).
21.
Mandon-Pépin B, Touraine P, Kuttenn F, Derbois C, Rouxel A, et al: Genetic investigation of four meiotic genes in women with premature ovarian failure. Eur J Endocrinol 158:107-115 (2008).
22.
Papadopoulou E, Sismani C, Christodoulou C, Ioannides M, Kalmanti M, Patsalis P: Phenotype-genotype correlation of a patient with a ‘balanced' translocation 9;15 and cryptic 9q34 duplication and 15q21q25 deletion. Am J Med Genet A 152A:1515-1522 (2010).
23.
Schalkwijk J, Zweers MC, Steijlen PM, Dean WB, Taylor G, et al: A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med 345:1167-1175 (2001).
24.
Schluth-Bolard C, Delobel B, Sanlaville D, Boute O, Cuisset JM, et al: Cryptic genomic imbalances in de novo and inherited apparently balanced chromosomal rearrangements: array CGH study of 47 unrelated cases. Eur J Med Genet 52:291-296 (2009).
25.
Sismani C, Kitsiou-Tzeli S, Ioannides M, Christodoulou C, Anastasiadou V, et al: Cryptic genomic imbalances in patients with de novo or familial apparently balanced translocations and abnormal phenotype. Mol Cytogenet 1:15 (2008).
26.
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, et al: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:4133-4160 (2010).
27.
Stankiewicz P, Lupski JR: Genome architecture, rearrangements and genomic disorders. Trends Genet 18:74-82 (2002).
28.
White PC, Bachega TA: Congenital adrenal hyperplasia due to 21 hydroxylase deficiency: from birth to adulthood. Semin Reprod Med 30:400-409 (2012).
29.
Wijesuriya SD, Zhang G, Dardis A, Miller WL: Transcriptional regulatory elements of the human gene for cytochrome P450c21 (steroid 21-hydroxylase) lie within intron 35 of the linked C4B gene. J Biol Chem 274:38097-38106 (1999).
30.
Wirth J, Nothwang HG, van der Maarel S, Menzel C, Borck G, et al: Systematic characterisation of disease associated balanced chromosome rearrangements by FISH: cytogenetically and genetically anchored YACs identify microdeletions and candidate regions for mental retardation genes. J Med Genet 36:271-278 (1999).
31.
Yang Y, Wang C, Wang F, Zhu L, Liu H, He X: Novel chromosomal translocation t(11;9)(p15;p23) involving deletion and duplication of 9p in a girl associated with autism and mental retardation. Gene 502:154-158 (2012).
32.
Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, et al: Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. Am J Hum Genet 73:214-217 (2003).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.